On April 15, 1992, Belley, Michel L.; Leblanc, Yves; Labelle, Marc published a patent.Safety of Isochroman-3-ol The title of the patent was Preparation of 7-phenyl-5-[(quinolylmethoxy)phenyl]-4-thiaheptanoates and analogs as leukotriene antagonists. And the patent contained the following:
R1YZCR7[X2r(CR3R3)mZ1n(CR3R22)pQ1]X3r'(CR3R3)m’Z2n'(CR3R4)p’CR2R3Q2 [Q1 = CO2R3, tetrazolyl, cyano, CONH2, etc.; Q2 = OH, amino; R1 = (substituted)-2-quinolyl; R2 = alkyl, alkenyl, CF3, Ph, CH2Ph, etc.; R3 = H, groups cited for R2; CR3R22 = amino acid residue; R4 = halo, NO2, cyano, groups cited for R3, etc.; R7 = H, alkyl; X2, X3 = O, SO0-2, (substituted) CH2; Y = CR3R3X1, X1CR3R3, NR3CO, etc.; X1 = O, SO0-2, NR3; Z = (substituted) phenylenediyl; Z1, Z2 = (substituted) phenylenediyl, heteroarylenediyl; m, m’, p, p’ = 0-8; n, n’, r, r’ = 0, 1] were prepared as leukotriene antagonists (no data). Thus, 7-chloro-2-(bromomethyl)quinoline was condensed with 3-HOC6H4CHO and the product converted in 3 steps to RCH2PPh3Br (R = quinolylmethoxyphenyl group Q) which was condensed with 1H-3-hydroxy-3,4-dihydro-2-benzopyran to give, after oxidation, 2-(MeO2C)C6H4CH2CH:CHR (R = Q). The latter was condensed with HSCH2CHMeCO2H to give, after MeMgBr treatment, title compound I (R = Q). The experimental process involved the reaction of Isochroman-3-ol(cas: 42900-89-0).Safety of Isochroman-3-ol
The Article related to quinolylmethoxyphenylthiaheptanoate preparation leukotriene antagonist, antiasthmatic quinolylmethoxyphenylthiaheptanoate preparation, antiinflammatory quinolylmethoxyphenylthiaheptanoate preparation and other aspects.Safety of Isochroman-3-ol
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts